Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model. - Wikidata - awgldk - TriplyDB

Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model.

Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model.

http://www.wikidata.org/entity/Q31131437

about

The Active Metabolite of Warfarin (3'-Hydroxywarfarin) and Correlation with INR, Warfarin and Drug Weekly Dosage in Patients under Oral Anticoagulant Therapy: A Pharmacogenetics Study A pharmacogenetics-based warfarin maintenance dosing algorithm from Northern Chinese patients.Warfarin dosage response related pharmacogenetics in Chinese population.Verification of pharmacogenetics-based warfarin dosing algorithms in Han-Chinese patients undertaking mechanic heart valve replacement A polymorphism at the translation start site of the vitamin D receptor gene is associated with the response to anti-osteoporotic therapy in postmenopausal women from southern Italy.Clinical application of a new warfarin-dosing regimen based on the CYP2C9 and VKORC1 genotypes in atrial fibrillation patients Clinical and genetic factors associated with warfarin maintenance dose in northern Chinese patients with mechanical heart valve replacement Frequency of Common VKORC1 Polymorphisms and Their Impact on Warfarin Dose Requirement in Pakistani Population.Frequency of Common CYP2C9 Polymorphisms and Their Impact on Warfarin Dose Requirement in Pakistani Population.Development of a pharmacogenetic-based warfarin dosing algorithm and its performance in Brazilian patients: highlighting the importance of population-specific calibration.Acenocoumarol Pharmacogenetic Dosing Algorithms and Their Application in Two Bulgarian Patients with Low Anticoagulant Requirements.Frequency of CYP2C9 and VKORC1 gene polymorphisms and their influence on warfarin dose in Egyptian pediatric patients.Genetic polymorphisms in very important pharmacogenomic variants in the Zhuang ethnic group of Southwestern China: A cohort study in the Zhuang population.Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants.Establishment of a Han Chinese-specific pharmacogenetic-guided warfarin dosing algorithm

P2860

Q28553937-88419C2A-4434-4117-B2FC-92AA3343D371 Q34050936-7AB8C4D1-2273-4A5F-B6AB-A342BCB69598 Q34977531-9AA4C94D-00EC-40F8-9111-FAD3646664C7 Q35146916-6CA62AB1-A123-4C41-B7D4-DE631DADEB4B Q35381094-750CEA57-9A94-47AC-BF87-BBA9A5BDBFDF Q36741112-C046B654-B2F5-4BDE-AA13-324FD9A28C67 Q37606335-51728C08-A6AF-47CB-8A9F-8C83FDA92BE3 Q39159490-8F0FFCBE-9F97-4E3B-AA92-49AC07B24D00 Q39676335-98D34043-6965-4938-B7E8-3A546C67E788 Q40862073-D43042FD-2A27-4B41-8C13-A71E89D3BEB6 Q43926562-F43D3D7F-AC64-4463-AA24-72DE7AD73B88 Q44367614-E3EC232C-0567-4BCC-9695-02017A7C4733 Q55281929-F9B643DA-F7E6-4C2A-87EF-74D114D10CEA Q55717925-D34F69E6-F47E-4D34-B7F3-1C5B71A511D8 Q58759165-9A566AB5-9F78-494F-8A75-28A06D6F30C1

P2860

Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model.

http://www.wikidata.org/entity/Q31131437

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model.

@ast

Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model.

@en

type

label

Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model.

@ast

Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model.

@en

prefLabel

Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model.

@ast

Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model.

@en

P1433

Q31131437-50CF7FED-0ED3-4D2A-8B97-5CBE3FEF5230

P1476

Q31131437-176566CC-D92E-421A-9A4A-89AB4B84C744

P2093

Q31131437-037D4538-9BF5-4AC8-AD13-F4C64D38C05F

Q31131437-1647FFA9-C36F-4721-B4A0-63F21B2F1110

Q31131437-40E120DD-90D2-48DA-A9CC-0728FF4B0F16

Q31131437-59D61071-4BA2-4965-8E14-6C688C20046E

Q31131437-69820914-353A-4BA9-8326-134ADC652F75

Q31131437-8602D1DA-735D-49D0-94D1-EE439DF57128

Q31131437-8A557BB0-323A-4224-9655-286A7FBEA9C3

Q31131437-9DF602F3-FFC1-4998-9B60-53390EAF22E5

Q31131437-AAAB1A44-1F6C-4678-91B2-296765893428

Q31131437-CB446ADB-2295-4D68-9959-8DBE9C56EBB7

P2860

Q31131437-0B57FBDF-4935-4185-81C9-2BBE77F21251

Q31131437-110A821D-4C16-4FD1-B664-207FFBD14C62

Q31131437-138773B3-B75E-4235-9FBE-5C68AEBCFCF3

Q31131437-16D27617-F676-4E75-8591-347E976F2C93

Q31131437-1C0CBB7C-3822-4B74-9779-A12577B18D63

Q31131437-2408CCDC-D170-4659-89CC-C64E29D0B893

Q31131437-2AEA9E7D-F429-4608-8F9F-739B3D885489

Q31131437-3455D1A3-3913-4BD7-AF88-D27B6DD31110

Q31131437-3F429028-800C-4C4A-85C9-2E8B4CF3E5BA

Q31131437-42C3D552-94B2-473D-9968-77C81E313E86

P304

Q31131437-59D07810-13C1-4340-8B0F-E2C817325772

P31

Q31131437-C058C8F1-D7D7-4BD0-82D6-49C3B553538F

P356

Q31131437-B4154E70-0BBA-4BFA-8BF4-35A633438742

P407

Q31131437-5A82FEAC-0FD1-4735-95B2-296C5243F7DB

P433

Q31131437-83A1872B-7490-4AC5-805C-D3ADECD13BD8

P478

Q31131437-F3899559-B14C-4017-BE87-F779302F14BC

P50

Q31131437-2418095A-47EC-4F0C-A8A3-1DC9A8E24C5C

P577

Q31131437-6A991AE0-023F-4891-9A8E-01B09D2ABF0F

P5875

Q31131437-8BA45D86-D76F-41B9-816F-552F285C047D

P698

Q31131437-91A580EC-3AAF-4C26-84E8-8EAF22784C9D

P921

Q31131437-0357C7CB-84B1-4141-960B-99AEA7768E5A

Q31131437-99D58968-1363-40E3-BA3A-F4DF0A2D8A7C

P932

Q31131437-3EB94608-A386-40F4-8E31-4C2C5AA5B558

P356

JOURNAL.PONE.0071505

P1433

P1476

Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model.

@en

P2093

Alfonso Meccariello

http://www.w3.org/2001/XMLSchema#string

Amelia Filippelli

http://www.w3.org/2001/XMLSchema#string

Angelo Severini

http://www.w3.org/2001/XMLSchema#string

Corrado Perricone

http://www.w3.org/2001/XMLSchema#string

Cristina Mazzaccara

http://www.w3.org/2001/XMLSchema#string

Dino Franco Vitale

http://www.w3.org/2001/XMLSchema#string

Lucia Sacchetti

http://www.w3.org/2001/XMLSchema#string

Mario Toriello

http://www.w3.org/2001/XMLSchema#string

Pasquale Meccariello

http://www.w3.org/2001/XMLSchema#string

Rosario Liguori

http://www.w3.org/2001/XMLSchema#string

P2860

Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction

CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant

3'-minor groove binder-DNA probes increase sequence specificity at PCR extension temperatures.

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing

Haploview: analysis and visualization of LD and haplotype maps

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients

Identification of the gene for vitamin K epoxide reductase

Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

Estimation of the warfarin dose with clinical and pharmacogenetic data.

P304

e71505

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0071505

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Vittorio Simeon

P577

2013-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256291927

http://www.w3.org/2001/XMLSchema#string

P698

23990957

http://www.w3.org/2001/XMLSchema#string

P921

anticoagulation

P932

3753327

http://www.w3.org/2001/XMLSchema#string